Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib

NCT05252988 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

177

Enrollment

OTHER

Sponsor class

Conditions

Early-stage Breast Cancer
HER2 Positive Breast Cancer
Hormone Receptor Positive

Interventions

DRUG: Neratinib
DRUG: Loperamide
DRUG: Colesevelam

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]
[object Object]